seful as antihypertensives. However, the development of the PSP-2745 has been arrested after a merger of the company, despite Sitagliptin DPP-4 inhibitor earlier reports of its specificity T and promising cardioprotective effects and renoprotective found Protective. Further studies are required to demonstrate that the aldosterone synthase inhibitors may be independent Ngig blood pressure, K Body temperature protection ¬ positive effects similar to those of mineralocorticoid receptor antagonists Of supply. In ergs Nzung to the specific aldosterone antagonists, some calcium channel blockers may block the mineralocorticoid Receptors28 of 30 or inhibit aldosterone synth ¬ sis.31 33 These initial data suggest that agents do not stero Dian with double or triple the effect on calcium channels Le, mineralocorticoid of the aldosterone and k nnte developed.6 natriuretic peptide receptor agonists be A-factors endogenous atrial natriuretic peptide and brain natriuretic peptide as a marker already major kardiovaskul re risk factors. These proteins Have natriuretic, vasorelaxant and antiproliferative effects, the tracks include responsibility for its actions to stimulate and activate streets enverwaltung guanylyl cyclase, with subsequent accumulation ¬ in cGMP, the PUTA ¬ Scopes positive effects in hypertension, heart failure, nephrosclerosis, and stroke. 34 knockdown or knockout of street enverwaltung leads to decreased formation of cGMP and high blood pressure, 35, w while, the administration of ANP endothelium-dependent Independent vasorelaxation 0.36 The street is enverwaltung antagonist ¬ PL 3994 is currently in a phase of clinical testing in patients with heart failure and hypertension.5 In phase I studies, dose- Independent PL 3994 has increased levels of cGMP ht, blood pressure, natriuresis and the n next day after treatment ¬ volunteers.37 healthy Similar results in a phase IIa study in patients with adequate controls is shown were induced EAA essential hypertension.38 In this study, patients treated with ACE inhibitors, the blood pressure of the gr-Run reduction effect, which has a synergy between street enverwaltung agonism and epoxide hydrolase blockade.38 ACE inhibitor identified as epoxide hydrolase been a new therapeutic target for the contr of blood pressure due to the inhibition had a hypotensive effect in spontaneously hypertensive rats, the angiotensin II-induced hypertension have, 39 but not in normotensive Wistar rats.40 has this enzyme inhibition and antiproliferative effects.41 AR 9281 is the first epoxide hydrolase inhibitor clinical trials has progressed. This drug is lipophilic, it can be administered orally, and it lowers blood pressure, continuous improvement of vascular Function and Maraviroc reduced kidney damage ¬ In rats with the angiotensin II hypertension.42 43 By contrast, induced AR 9281 not urs chlich for the hypotensive effect in healthy subjects, although it inhibited the epoxide hydrolase and was good in 8, dose-finding study of a single loading dose and multiple-dose treatment.44 However, high activity t of epoxide hydrolase in patients with hypertension and diabetes mellitus, 44 describes the r m watching resembled the RA 9281 in these indications. Angiotensin II receptor agonists in type 2 Our group has identified as an m Possible AT2R.